GlassScriptPhysician profile
Haleh Tabrah
NPI 1083640353
$1,738.13
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,269 · 2020: $247 · 2021: $133 · 2022: $32.07 · 2023: $57.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $57.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $57.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $462.14 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $313.89 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $205.61 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $199.36 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $195.11 | 2019-2021 | |
| Abbvie INC. | $97.39 | 2021-2023 | Vraylar |
| Allergan, INC. | $78.48 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $52.86 | 2019-2020 | |
| Indivior INC. | $42.06 | 2019 | |
| Corium, LLC | $34.99 | 2023 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.69 | 2021 | |
| Vanda Pharmaceuticals INC. | $17.07 | 2020 | |
| Ironshore Pharmaceuticals INC. | $14.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haleh Tabrah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.